Background Malaria remains a major global public health concern, especially in sub-
Saharan Africa. The RTS, S/AS01 malaria candidate vaccine was reviewed by the European …

Background The efficacy of RTS, S/AS01 as a vaccine for malaria is being tested in a phase
3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria …

Considerable progress has been made in malaria control in the last two decades, but
progress has stalled in the last few years. New tools are needed to achieve public health …

Abstract Development and Phase 3 testing of the most advanced malaria vaccine, RTS,
S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of …

Background The RTS, S/AS02D vaccine has been shown to have a promising safety profile,
to be immunogenic and to confer protection against malaria in children and infants. Methods …

Background Controlled infection studies in malaria-naive adults suggest increased vaccine
efficacy for fractional-dose versus full-dose regimens of RTS, S/AS01. We report first results …

In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …

RTS, S/AS02A is a pre-erythrocytic vaccine candidate based on the Plasmodium falciparum
circumsporozoite surface antigen and is currently the most advanced malaria vaccine …

Background The pre-erythrocytic malaria vaccine RTS, S/AS02A has shown to confer
protection against clinical malaria for at least 21 months in a trial in Mozambican children …

Summary Background RTS, S/AS02A is a pre-erythrocytic stage malaria vaccine that
provides partial protection against infection in malaria-naive adult volunteers and …